ArticleVirologica Sinica2025
Predicting mortality risk of severe fever with thrombocytopenia syndrome: A multi-center retrospective cohort study.
Article in Virologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A potent Gc neutralizing antibody reveals architecture-dependent bispecific protection against SFTSV.Emerging microbes & infections · 2026Article
- Hyper-activated low-density neutrophil-derived NGAL predicts fatal SFTS: a multi-cohort and single-cell study.Infection · 2026Article
- Methyltransferase METTL1 Upregulates USF2 in a m7G-Dependent Manner to Accelerate Septic Cardiomyopathy by Inactivating PINK1/Parkin-Mediated Mitophagy.Cardiovascular toxicology · 2026Article
- An Explainable Machine Learning Model for Early Prediction of Incident Myocardial Injury in Patients With Severe Fever With Thrombocytopenia Syndrome.Journal of medical virology · 2026Article
- Aspartate aminotransferase-to-lymphocyte ratio predicts in-hospital mortality in patients with severe fever with thrombocytopenia syndrome: a multicenter retrospective cohort study.BMC infectious diseases · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease with high mortality, and clinical practice lacks dynamic tools to assess its rapidly evolving course. This study aims to develop stage-specific machine learning models to predict mortality risk using longitudinal biomarker data. We conducted a retrospective analysis of 5359 laboratory-confirmed SFTS patients from two hospitals in the highly endemic region in China. Serial measurements of 46 clinical and laboratory variables were integrated into a three-stage prognostic model developed using extreme gradient boosting (XGBoost). Within each clinical stage, key predictors and their relative contribution (RC) of mortality risk were assessed. Model performance was assessed based on discrimination, calibration, and decision curve analysis (DCA) in internal and external test sets. XGBoost models were constructed across 10 temporal phases, later consolidated into three clinically distinct stages via hierarchical clustering: early (≤7 days), intermediate (days 8-9), and late (≥10 days). Key predictors included age (dominant in early phase; RC, 18.44%), lactate dehydrogenase (LDH; RC peaking at 60.10% in late phase), and monocyte percentage (RC range from 5.25% to 16.04%). Pathophysiological shifts across clinical stages were revealed: early viral cytopathy (dominated by age and MONO%), intermediate immunopathology (marked by LDH surge), and late hepatic failure (dominated by LDH, AST, and TBA). The model showed strong discrimination (Area under the receiver operating characteristic curve, AUCs: 0.84-0.98 internal; 0.91-0.98 external), calibration (Brier scores: 0.04-0.11), and clinical utility via DCA. This study introduces a dynamic staging system that leverages predictive models and real-time patient data to monitor mortality risk and personalize SFTS care, which enables timely interventions to reduce deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.